Oncorus, Inc.

Calculating rank

USPTO Granted Patents = 6

% Expired Patents = 16.7

EPO Patents = 1

Forward Citations = 8

Loading Chart...

8 inventors (with patents filed for the assignee):

Mitchell H Finer (4 out of 6 patents)

Luke Evnin (2 out of 4 patents)

Kenneth P Greenberg (2 out of 2 patents)

4. Christophe Quéva (2 out of 3 patents)

5. Lorena Lerner (2 out of 3 patents)

6. Edward Kennedy (1 out of 2 patents)

7. Gholamreza Hassanzadeh Ghassabeh (1 out of 1 patent)

8. Sonia Feau (1 out of 1 patent)

6 patents: Sort by Forward Citations

1. 12686725 - ANTI-DLL3 ANTIBODIES AND METHODS OF USE (2026-07-21),

2. 11612625 - Oncolytic viral vectors and uses thereof (2023-03-28),

3. 11452750 - Oncolytic viral vectors and uses thereof (2022-09-27),

4. 11078280 - Oncolytic viral delivery of therapeutic polypeptides (2021-08-03),

5. 10604574 - Oncolytic viral delivery of therapeutic polypeptides (2020-03-31),

6. 10391132 - Oncolytic viral vectors and uses thereof (2019-08-27),

Company Overview

Oncorus is a biotechnology company focused on developing next-generation viral immunotherapies to combat cancer. The company's innovative platform combines viral vectors with immunotherapies to create more effective treatments for patients. Oncorus is dedicated to advancing the field of oncolytic viruses and improving outcomes for cancer patients.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

6 Patents

#324 in Cambridge, MA

#2,548 in Massachusetts

#45,030 in US

Cambridge, MA, United States of America

Oncorus, Inc.

Forward Citations = 8

8 inventors:

Mitchell H Finer (4 out of 6 patents)

Luke Evnin (2 out of 4 patents)

Kenneth P Greenberg (2 out of 2 patents)

4. Christophe Quéva (2 out of 3 patents)

5. Lorena Lerner (2 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Oncorus, Inc.. Retrieved from https://idiyas.com/company/oncorus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]